Asenapine: A new focus on the treatment of mania

Cruz, Núria; Vieta, Eduard

doi:10.1016/S2173-5050(11)70016-4

Información del artículo

Resumen

Bibliografía

Descargar PDF

Estadísticas

Abstract

Development

Asenapine, recently marketed in United States and ready to be so in Europe, is a multimodal action second-generation antipsychotic, with high affinity for multiple dopaminergic (D2, D3 y D4), serotonergic (5HT1A, 5HT2B, 5HT2C, 5HT6 y 5HT7) and adrenergic (α1A, α2A, α2B y α2C) receptors. Asenapine has to be administered sublingually. After going through succesfully the preliminary phases of development, several clinical trials have been completed in two main indications: schizophrenia and mania. This article summarizes the available evidence on its safety and efficacy in acute mania and provides some prospect on its clinical immediate and future applications.

Conclusions

Asenapine is effective and generally well tolerated in the treatment of moderate-to-severe acute mania associated to bipolar I disorder. The sublingual administration may be a challenge (coadministration with food or other drugs needs to be avoided) but also an opportunity (improved treatment adherence). Due to its multimodal receptor profile, it may cause several side-effects, but most of those are relatively mild, with none being particularly outstanding. In Europe, asenapine is indicated for the treatment of acute mania only, but several trials are being conducted in schizophrenia and bipolar depression.

Keywords:

Asenapine

Antipsychotic

Mania

Bipolar disorder

Resumen

Desarrollo

La asenapina, recientemente comercializada en Estados Unidos y presta a serlo en Europa, es un antipsicótico de segunda generación con acción multimodal, derivada de su afinidad por múltiples receptores dopaminérgicos (D2, D3 y D4), serotonérgicos (5HT2A, 5HT2B, 5HT2C, 5HT6 y 5HT7) y adrenérgicos (αa1A, α2A, α2B y α2C). Su administración se realiza por vía sublingual. Tras culminar las fases iniciales de desarrollo, se han conducido diversos ensayos clínicos en dos indicaciones principalmente: esquizofrenia y manía. Este artículo sintetiza la evidencia científica de su eficacia y seguridad en manía aguda y adelanta algunas de sus posibilidades clínicas inmediatas y futuras.

Conclusiones

La asenapina es eficaz y generalmente bien tolerada en el tratamiento de la manía aguda moderada o grave asociada al trastorno bipolar tipo I. Su administración sublingual plantea el reto de evitar su coadministración con comida u otros fármacos, pero puede suponer una ventaja para la adherencia terapéutica. Por su perfil multimodal, puede asociarse a diversos efectos adversos, pero destaca por la baja intensidad de todos ellos, sin ninguno que sobresalga por encima de los demás. En Europa está indicada solamente para la manía aguda, pero se están realizando también numerosos ensayos en esquizofrenia y en depresión bipolar.

Palabras clave:

Asenapina

Antipsicótico

Manía

Trastorno bipolar

El Texto completo está disponible en PDF

References

[1.]

United States Food and Drug Administration. FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder. Press release, 14 August 2007. [Accessed August 2009] Available in: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm177401.htm

[2.]

Schering-Plough Corporation. Saphris (Asenapine) Sublingual Tablets US Prescribing Information. Revised August 2009. [Accessed August 2009] Available in: http://www.spfiles.com/pisaphrisv1.pdf

[3.]

E. Vieta, J. Sanchez-Moreno.

Acute and long-term treatment of mania.

Dialogues Clin Neurosci, 10 (2008), pp. 165-179

Medline

[4.]

Stevenson R, Wolde HT. Update 4 - Akzo, Pfizer Scrap Asenapine Joint Development. 28 November 2006. [Accessed August 2009] Available in: http://www.reuters.com/article/companyNews AndPR/idUSL286087420061128

[5.]

United States Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. 30 July 2009. [Accessed August 2009] Available in: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf

[6.]

B. Costall, A.M. Domeney, M.E. Kelly, R.J. Naylor, D.M. Tomkins.

Actions of ORG 5222 as a novel psychotropic agent.

Pharmacol Biochem Behav, 35 (1990), pp. 607-615

Medline

[7.]

S.G. Potkin, M. Cohen, J. Panagides.

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidonecontrolled trial.

J Clin Psychiatry, 68 (2007), pp. 1492-1500

Medline

[8.]

M. Shahid, G.B. Walker, S.H. Zorn, E.H. Wong.

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

J Psychopharmacol, 23 (2009), pp. 65-73

http://dx.doi.org/10.1177/0269881107082944 | Medline

[9.]

H.Y. Meltzer.

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Psychopharmacology (Berl), 99 (1989), pp. S18-S27

[10.]

H.Y. Meltzer.

The role of serotonin in antipsychotic drug action.

Neuropsychopharmacology, 21 (1999), pp. 106S-115S

http://dx.doi.org/10.1016/S0893-133X(99)00046-9 | Medline

[11.]

B.L. Roth, S.M. Hanizavareh, A.E. Blum.

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Psychopharmacology (Berl), 174 (2004), pp. 17-24

[12.]

F.I. Tarazi, T. Moran-Gates, E.H. Wong, B. Henry, M. Shahid.

Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Psychopharmacology (Berl), 198 (2008), pp. 103-111

[13.]

M. Huang, Z. Li, J. Dai, M. Shahid, E.H. Wong, H.Y. Meltzer.

Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.

Neuropsychopharmacology, 33 (2008), pp. 2934-2945

http://dx.doi.org/10.1038/npp.2008.20 | Medline

[14.]

L.N. Yatham, J.M. Goldstein, E. Vieta, C.L. Bowden, H. Grunze, R.M. Post, et al.

Atypical antipsychotics in bipolar depression: potential mechanisms of action.

J Clin Psychiatry, 66 (2005), pp. 40-48

Medline

[15.]

E. Brugue, E. Vieta.

Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications.

Prog Neuropsychopharmacol Biol Psychiatry, 31 (2007), pp. 275-282

http://dx.doi.org/10.1016/j.pnpbp.2006.06.014 | Medline

[16.]

A.C. Neale, H. Jenkins, D. Amend, M. Lesen.

A 14 day dose escalation, double-blind, randomized, placebo-controlled study of SB518 in adult patients with schizophrenia [abstract].

Neuropsychopharmacology, 30 (2005), pp. S54

[17.]

P.B. Hedlund, J.G. Sutcliffe.

Functional, molecular and pharmacological advances in 5-HT7 receptor research.

Trends Pharmacol Sci, 25 (2004), pp. 481-486

http://dx.doi.org/10.1016/j.tips.2004.07.002 | Medline

[18.]

T.H. Svensson.

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.

Prog Neuropsychopharmacol Biol Psychiatry, 27 (2003), pp. 1145-1158

http://dx.doi.org/10.1016/j.pnpbp.2003.09.009 | Medline

[19.]

J.N. Joyce, M.J. Millan.

Dopamine D3 receptor antagonists as therapeutic agents.

Drug Discov Today, 10 (2005), pp. 917-925

http://dx.doi.org/10.1016/S1359-6446(05)03491-4 | Medline

[20.]

H.M. Marston, J.W. Young, F.D. Martin, K.A. Serpa, C.L. Moore, E.H. Wong, et al.

Asenapine effects in animal models of psychosis and cognitive function.

Psychopharmacology (Berl), 206 (2009), pp. 699-714

[21.]

J.D. Jentsch, M. Shahid, E. Wong, R.H. Roth.

Asenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine.

Schizophr Res, 81 (2006), pp. 85

[22.]

F.I. Tarazi, Y.K. Choi, M. Gardner, E.H. Wong, B. Henry, M. Shahid.

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain.

Synapse, 63 (2009), pp. 413-420

http://dx.doi.org/10.1002/syn.20618 | Medline

[23.]

D.E. Johnson, H. Yamazaki, K.M. Ward, A.W. Schmidt, W.S. Lebel, J.L. Treadway, et al.

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets.

Diabetes, 54 (2005), pp. 1552-1558

Medline

[24.]

M. Gervin, T.R.E. Barnes.

Assessment of drug-related movement disorders in Schizophrenia.

Adv Psychiatr Treat, 6 (2000), pp. 332-341

[25.]

E.M. Weiss, R.M. Bilder, W.W. Fleischhacker.

The effects of secondgeneration antipsychotics on cognitive functioning and psychosocial outcome in Schizophrenia.

Psychopharmacology (Berl), 162 (2002), pp. 11-17

[26.]

Peeters P, De Greef R, Hulskotte E, et al. Asenapine: an overview of phase I pharmacokinetic studies. 2009. Paris, France, Poster presented at 9th World Congress of Biological Psychiatry, 28 June-2 July 2009.

[27.]

R.S. McIntyre, M. Cohen, J. Zhao, L. Alphs, T.A. Macek, J. Panagides.

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.

J Affect Disord, 122 (2010), pp. 27-38

http://dx.doi.org/10.1016/j.jad.2009.12.028 | Medline

[28.]

R.S. McIntyre, M. Cohen, J. Zhao, L. Alphs, T.A. Macek, J. Panagides.

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.

Bipolar Disord, 11 (2009), pp. 673-686

http://dx.doi.org/10.1111/j.1399-5618.2009.00748.x | Medline

[29.]

R.S. McIntyre, M. Cohen, J. Zhao, L. Alphs, T.A. Macek, J. Panagides.